A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder / Maria A. Sullivan en The American Journal of Psychiatry, Año 2019 - Vol. 176 - No.2 (Febrero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2019 - Vol. 176 - No.2 (Febrero) . - pp. 129-137 Título : A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder Tipo de documento: texto impreso Autores: Maria A. Sullivan, Autor ; Adam Bisaga, Autor ; Martina Pavlicova, Autor Fecha de publicación: 2019 Artículo en la página: pp. 129-137 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Inyección de naltrexona, Antagonista opioide, Trastorno de uso de opioides, Naltrexona oral, Retención de tratamiento Resumen: The oral formulation of the opioid antagonist naltrexone has shown limited effectiveness for treatment of opioid use disorder due to poor adherence. Long-acting injection naltrexone (XR-naltrexone), administered monthly, circumvents the need for daily pill taking, potentially improving adherence, and has been shown to be superior to placebo in reducing opioid use over 6 months of treatment. Link: ./index.php?lvl=notice_display&id=20489 [artículo] A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder [texto impreso] / Maria A. Sullivan, Autor ; Adam Bisaga, Autor ; Martina Pavlicova, Autor . - 2019 . - pp. 129-137. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2019 - Vol. 176 - No.2 (Febrero) . - pp. 129-137 Palabras clave: Inyección de naltrexona, Antagonista opioide, Trastorno de uso de opioides, Naltrexona oral, Retención de tratamiento Resumen: The oral formulation of the opioid antagonist naltrexone has shown limited effectiveness for treatment of opioid use disorder due to poor adherence. Long-acting injection naltrexone (XR-naltrexone), administered monthly, circumvents the need for daily pill taking, potentially improving adherence, and has been shown to be superior to placebo in reducing opioid use over 6 months of treatment. Link: ./index.php?lvl=notice_display&id=20489

---

1 (1 - 1 / 1)